These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 25770888)

  • 1. Outcomes of Modestly Hypofractionated Radiation for Lung Tumors: Pre- and Mid-Treatment Positron Emission Tomography-Computed Tomography Metrics as Prognostic Factors.
    Harris JP; Chang-Halpenny CN; Maxim PG; Quon A; Graves EE; Diehn M; Loo BW
    Clin Lung Cancer; 2015 Nov; 16(6):475-85. PubMed ID: 25770888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET Predicts Pain Response and Local Control in Palliative Radiotherapy With or Without Systemic Treatment in Patients With Bone Metastasis From Non-small-cell Lung Cancer.
    Zhao F; Ding G; Huang W; Li M; Fu Z; Yang G; Kong L; Zhang Y; Yu J
    Clin Lung Cancer; 2015 Nov; 16(6):e111-9. PubMed ID: 25736696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
    Agolli L; Valeriani M; Bracci S; Nicosia L; DE Sanctis V; Enrici RM; Osti MF
    Anticancer Res; 2015 Oct; 35(10):5693-700. PubMed ID: 26408745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy.
    Abelson JA; Murphy JD; Trakul N; Bazan JG; Maxim PG; Graves EE; Quon A; Le QT; Diehn M; Loo BW
    Lung Cancer; 2012 Dec; 78(3):219-24. PubMed ID: 23009727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer.
    Ong LT; Dunphy M; Foster A; Woo KM; Zhang Z; Perez CA; Pietanza CM; Rosenzweig KE; Gelblum DY; Rimner A; Wu AJ
    Clin Lung Cancer; 2016 May; 17(3):184-8. PubMed ID: 26320828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer.
    Gensheimer MF; Hong JC; Chang-Halpenny C; Zhu H; Eclov NCW; To J; Murphy JD; Wakelee HA; Neal JW; Le QT; Hara WY; Quon A; Maxim PG; Graves EE; Olson MR; Diehn M; Loo BW
    Radiother Oncol; 2017 Nov; 125(2):338-343. PubMed ID: 28830717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response criteria in solid tumors (PERCIST/RECIST) and SUV
    Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
    Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic evaluations of small size lung cancers by 18F-FDG PET/CT and thin-section CT.
    Kishimoto M; Iwano S; Ito S; Kato K; Ito R; Naganawa S
    Lung Cancer; 2014 Nov; 86(2):180-4. PubMed ID: 25263854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.
    Kohutek ZA; Wu AJ; Zhang Z; Foster A; Din SU; Yorke ED; Downey R; Rosenzweig KE; Weber WA; Rimner A
    Lung Cancer; 2015 Aug; 89(2):115-20. PubMed ID: 26078260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography as a predictor of response in locally advanced non-small-cell carcinoma of the lung.
    Roy S; Pathy S; Kumar R; Mohanti BK; Raina V; Jaiswal A; Taywade S; Garg K; Thulkar S; Mohan A; Mathur S; Behera D
    Nucl Med Commun; 2016 Feb; 37(2):129-38. PubMed ID: 26544097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer.
    Hasselle MD; Haraf DJ; Rusthoven KE; Golden DW; Salgia R; Villaflor VM; Shah N; Hoffman PC; Chmura SJ; Connell PP; Vokes EE; Weichselbaum RR; Salama JK
    J Thorac Oncol; 2012 Feb; 7(2):376-81. PubMed ID: 22198429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of pre-treatment
    Aktan M; Koc M; Kanyilmaz G; Yavuz BB
    Ann Nucl Med; 2017 Jul; 31(6):462-468. PubMed ID: 28516335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
    Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
    J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning.
    Coon D; Gokhale AS; Burton SA; Heron DE; Ozhasoglu C; Christie N
    Clin Lung Cancer; 2008 Jul; 9(4):217-21. PubMed ID: 18650169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
    Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
    Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical study.
    Takahashi N; Yamamoto T; Matsushita H; Sugawara T; Kubozono M; Umezawa R; Ishikawa Y; Kozumi M; Katagiri Y; Tasaka S; Takeda K; Takeda K; Dobashi S; Jingu K
    J Radiat Res; 2016 Nov; 57(6):655-661. PubMed ID: 27422935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can adaptive threshold-based metabolic tumor volume (MTV) and lean body mass corrected standard uptake value (SUL) predict prognosis in head and neck cancer patients treated with definitive radiotherapy/chemoradiotherapy?
    Akagunduz OO; Savas R; Yalman D; Kocacelebi K; Esassolak M
    Nucl Med Biol; 2015 Nov; 42(11):899-904. PubMed ID: 26275933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer.
    Campeau MP; Herschtal A; Wheeler G; Mac Manus M; Wirth A; Michael M; Hogg A; Drummond E; Ball D
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1371-5. PubMed ID: 19250769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.